
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc shows a promising growth trajectory in its Precision Diagnostics and Radiopharmaceutical Oncology sectors, highlighted by the anticipated increase in market share for the POSLUMA PSMA PET imaging product, which is expected to achieve high single-digit revenue and unit share growth by the first quarter of 2025. The introduction of an enhanced Pylarify formulary—boosting batch sizes by approximately 50%—is projected to reinvigorate growth starting in the fourth quarter of 2026, supported by three years of TPT eligibility. Furthermore, the potential for significant contributions from non-Pylarify segments may exceed current growth and margin models, thereby enhancing the company’s earnings per share expectations for 2026 and 2027.
Bears say
Lantheus Holdings Inc. has reported a decline in Pylarify revenue, amounting to $260 million, which represents an 8% year-over-year decrease and fell approximately $14 million short of consensus estimates, indicating weaker demand than anticipated. Additionally, the company's unit growth was considerably lower than expected, recording only a 2% increase year-over-year amid a significant 10% price headwind. The downward revision of Pylarify growth forecasts for 2025-2026, combined with Lantheus’s overall growth profile trailing behind profitable SMID MedTech peers, further underscores the challenges the company faces in maintaining market competitiveness.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares